FDA Drug Label
EGRIFTA (tesamorelin) for injection - Prescribing Information
Theratechnologies, 2010
GH SecretagoguesFDA ApprovedS
Tesamorelin
Egrifta
Tesamorelin (brand: Egrifta SV) is the only FDA-approved GHRH analog, indicated for reduction of excess visceral abdominal fat (lipodystrophy) in HIV-positive adults on antiretroviral therapy. Phase III clinical trials demonstrated significant visceral adipose tissue (VAT) reduction, improved triglyceride profiles, and increased IGF-1 at 2 mg daily dosing. Available by prescription through specialty pharmacies and telehealth.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 8
- Research grade
- S
- Experience
- 56
- Activity
- 42
Overall check-ins
Trackers & reports
Overview
About Tesamorelin
Tesamorelin (brand: Egrifta SV) is the only FDA-approved GHRH analog, indicated for reduction of excess visceral abdominal fat (lipodystrophy) in HIV-positive adults on antiretroviral therapy. Phase III clinical trials demonstrated significant visceral adipose tissue (VAT) reduction, improved triglyceride profiles, and increased IGF-1 at 2 mg daily dosing. Available by prescription through specialty pharmacies and telehealth.
- Category
- GH Secretagogues
- Regulatory status
- FDA Approved
- Also known as
- Egrifta
- Self-reports
- 114
Community
What 114 users report
114 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 3% · Mixed 97% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
224
Sleep
1
Recovery
1
Libido
1
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Injection site irritation
113
Water retention
106
Self-reported dose per injection
Median bucket: 1–2 mg · Most common: 1–2 mg
Reports span 0 to ≥ 5 mg (open-ended top bucket)
0–0.01 mg
9
0.1–0.2 mg
1
0.2–0.4 mg
5
0.4–0.6 mg
5
0.6–1 mg
4
1–2 mg
126
2–3 mg
74
5+ mg
1
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 88% said they felt similar to their last entry, 12% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 46 days · Based on 41 repeat reporters
Research
Cited research (6)
Source
PubMed
Growth hormone-releasing peptides: clinical applications
Ghigo et al., 2008
ClinicalTrials.gov
Tesamorelin HIV lipodystrophy studies on ClinicalTrials.gov
ClinicalTrials.gov, 2024
FDA Drug Label
EGRIFTA SV (tesamorelin) for injection - Prescribing Information
Theratechnologies, 2019
PubMed
Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy
Spooner et al., 2012
PubMed
Tesamorelin
Unknown, 2018
Tools
Explore more
Explore
More ways to learn about Tesamorelin from observational PeptIQ data.
Compare with
Related peptides
Help
Frequently asked
What do PeptIQ users report about Tesamorelin?
This page summarizes 114 anonymized self-reports from PeptIQ users who track Tesamorelin, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for Tesamorelin?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for Tesamorelin?
6 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is Tesamorelin safe to use?
This wiki does not assess safety or recommend use. Tesamorelin is listed as FDA Approved. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of Tesamorelin?
Research, primarily in animal models, suggests Tesamorelin may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceWhat is the legal status of Tesamorelin?
Tesamorelin is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified Tesamorelin as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceWhat are the known or theoretical side effects and risks of Tesamorelin?
The safety and effectiveness of Tesamorelin have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhat is the current state of research on Tesamorelin?
While there are over 200 published studies on Tesamorelin, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source